Compared to individuals who carried the combination of MAD1L1 Arg/Arg and MAD2L1 Leu/Leu genotypes, we observed that individuals with MAD1L1 His/His and MAD2L1 Leu/Met or Met/Met genotypes had an increased risk of OR for CRC risk, up to 2.92 (95% CI: 1.63–5.24). This evidence concerns the gene MAD1L1 and colorectal carcinoma.